Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients
about
Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-ReviewBeyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer GenesDiagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal-Dominant Hereditary Connective Tissue DiseaseEndometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Universal molecular screening does not effectively detect Lynch syndrome in clinical practiceMulti-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patientsClinical diagnostic exome evaluation for an infant with a lethal disorder: genetic diagnosis of TARP syndrome and expansion of the phenotype in a patient with a newly reported RBM10 alteration.The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.Detecting PKD1 variants in polycystic kidney disease patients by single-molecule long-read sequencing.Counselling framework for moderate-penetrance cancer-susceptibility mutations.Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.A genome sequencing program for novel undiagnosed diseases.Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscapeExome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2.Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohortContralateral Prophylactic Mastectomy: Challenging Considerations for the SurgeonCurrent practices and guidelines for clinical next-generation sequencing oncology testingGenetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast CancerHereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era.Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testingGenetic tests to identify risk for breast cancer.Genomic Biomarkers for Breast Cancer Risk.IDICAP: A Novel Tool for Integrating Drug Intervention Based on Cancer Panel.Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.Candidate-gene criteria for clinical reporting: diagnostic exome sequencing identifies altered candidate genes among 8% of patients with undiagnosed diseases.Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment.The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel.Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine.Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities.Cancer Genetic Counseling and Testing in an Era of Rapid Change.Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance.The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
P2860
Q26744522-EB49AC37-C0B4-4D7D-AB36-CCDDC4E611E9Q28072478-AE18EFD4-FE25-41D1-8D73-580B6AA87C02Q28118637-2AA7745D-4C3F-4336-9533-E010131E5EECQ30234614-9BA91EDE-E479-4FB1-9D18-99A950ACFC1EQ33440778-E33D5E10-A024-4DC0-9555-241FBE44A180Q33605565-FDC39403-F805-4D72-9CE8-97BA9D62F0A1Q33618262-D840CAED-E621-4C71-BD2B-5C28E7317047Q33755919-051EC05A-91D1-403C-B784-19C0662BAE85Q33784408-E5E65BF4-CC4B-4DC4-B742-BD33CFF7EA6EQ33845711-1DD84C88-D1DE-4775-A4CD-6E173A9EE15EQ33911135-84074074-5DF1-4647-998F-B29BA9B58BE2Q34550417-0002D2DC-6CA1-47B2-8499-E9032005D66EQ34996647-9DF62795-D0C1-4A8D-9567-1DA09BBB1778Q35736188-17AA605D-A9C6-4D73-98A6-5CD31C7C7843Q36074256-3BFE2809-4189-45C3-BFDC-AB6A9192C33FQ36098650-8370849C-511F-443D-80FE-F84EAB0C2E56Q36101775-06AE59CE-63AB-4BD4-ADD9-9C4F9B2BB4EEQ36239238-5C2AA43A-35FE-48AC-A2DC-CF1891448B9DQ36267724-7E75DBEA-6681-4BD1-BFCD-761CB49BE3D9Q36274770-6F289CDA-19F6-4C6E-B29B-56B25AFA1330Q36808649-532B7A34-19C0-49B1-8F3A-C6E16DCF9018Q36812287-8E9AD4A6-469A-44B5-A282-BD402E8834ACQ36849663-7723C1F4-3DB4-4A16-B030-1727827C034AQ36849670-1A0E5394-C234-4868-AC18-811C0BFE2F6FQ36890898-A26EF4F1-8776-4EE6-93D8-1A4639339179Q37011929-C048E5DA-45F6-4666-8E9B-5770450435D3Q37176931-A6F11456-2C24-4CB6-883D-513ED4039EC9Q37207327-E26D1E6E-8F31-430C-9E7B-28723AA55621Q37242239-528C8608-A198-493D-8DF9-3365ADEE937FQ37542355-3D4744EA-4209-456D-9405-1AAACBE609C5Q37554531-5C4D3008-38C1-4E9A-9278-F619E0E6DF37Q37637598-2D2602AB-DB5C-491D-96F6-B1FBD9F6C997Q37666821-BFBC0EC2-6375-457E-96DE-C79AE531C203Q37709203-50CBB890-43E9-41B1-9938-9DD9C8603918Q38614725-7EE4C024-5A18-4E52-A3A9-B3FB80889835Q38616603-6C30D10A-CBEE-48B6-9BAB-E56CDFB2D42CQ38646561-5404D870-9055-4BE8-811E-89EFA8CF6E15Q38691948-77FC1A6B-1F2D-4B22-8E69-768E1495A638Q38765255-C6BC16E7-9646-4A7B-B89B-7D0E119DCB09Q38821634-10526138-42A2-40F8-8FD2-BAF7D200158A
P2860
Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Utilization of multigene panel ...... is of more than 2,000 patients
@ast
Utilization of multigene panel ...... is of more than 2,000 patients
@en
Utilization of multigene panel ...... is of more than 2,000 patients
@nl
type
label
Utilization of multigene panel ...... is of more than 2,000 patients
@ast
Utilization of multigene panel ...... is of more than 2,000 patients
@en
Utilization of multigene panel ...... is of more than 2,000 patients
@nl
prefLabel
Utilization of multigene panel ...... is of more than 2,000 patients
@ast
Utilization of multigene panel ...... is of more than 2,000 patients
@en
Utilization of multigene panel ...... is of more than 2,000 patients
@nl
P2093
P2860
P356
P1433
P1476
Utilization of multigene panel ...... is of more than 2,000 patients
@en
P2093
A J Stuenkel
Chia-Ling Gau
Divya Shah
Elaine Chen
Elizabeth Chao
Erika Palmaer
Holly LaDuca
Jill S Dolinsky
Kamelia Shoaepour
Stephanie Gandomi
P2860
P2888
P304
P356
10.1038/GIM.2014.40
P407
P577
2014-04-24T00:00:00Z